Your browser doesn't support javascript.
loading
Exploring the Translational Gap of a Novel Class of Escherichia coli IspE Inhibitors.
Ropponen, Henni-Karoliina; Diamanti, Eleonora; Johannsen, Sandra; Illarionov, Boris; Hamid, Rawia; Jaki, Miriam; Sass, Peter; Fischer, Markus; Haupenthal, Jörg; Hirsch, Anna K H.
Affiliation
  • Ropponen HK; Drug Discovery and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Diamanti E; Saarland University, Department of Pharmacy, Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Johannsen S; Current address: AMR Action Fund GP GmbH, Messeplatz 10, 4058, Basel, Switzerland.
  • Illarionov B; Drug Discovery and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Hamid R; Drug Discovery and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Jaki M; Saarland University, Department of Pharmacy, Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Sass P; Hamburg School of Food Science, Institute of Food Chemistry, Grindelallee 117, 20146, Hamburg, Germany.
  • Fischer M; Drug Discovery and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Haupenthal J; Saarland University, Department of Pharmacy, Campus Building E8.1, 66123, Saarbrücken, Germany.
  • Hirsch AKH; Drug Discovery and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus Building E8.1, 66123, Saarbrücken, Germany.
ChemMedChem ; 18(19): e202300346, 2023 10 04.
Article in En | MEDLINE | ID: mdl-37718320
ABSTRACT
Discovery of novel antibiotics needs multidisciplinary approaches to gain target enzyme and bacterial activities while aiming for selectivity over mammalian cells. Here, we report a multiparameter optimisation of a fragment-like hit that was identified through a structure-based virtual-screening campaign on Escherichia coli IspE crystal structure. Subsequent medicinal-chemistry design resulted in a novel class of E. coli IspE inhibitors, exhibiting activity also against the more pathogenic bacteria Pseudomonas aeruginosa and Acinetobacter baumannii. While cytotoxicity remains a challenge for the series, it provides new insights on the molecular properties for balancing enzymatic target and bacterial activities simultaneously as well as new starting points for the development of IspE inhibitors with a predicted new mode of action.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Escherichia coli Proteins / Escherichia coli Limits: Animals Language: En Journal: ChemMedChem Journal subject: FARMACOLOGIA / QUIMICA Year: 2023 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Escherichia coli Proteins / Escherichia coli Limits: Animals Language: En Journal: ChemMedChem Journal subject: FARMACOLOGIA / QUIMICA Year: 2023 Document type: Article Affiliation country: Alemania